The oncogenes within the sequenced gene panel had a total of 22 out of 121 validated variants (PIK3CA (7/121 [6%]), BRAF (5/121 [4%]), KRAS (7/121 [6%]), SOX9 (3/121 [2%])). We previously reported on variants targeting BRAF and KRAS in African Americans with colorectal cancer, however the present data seems to give weight to other oncogenes such as PIK3CA as major targets of variants. This evidence concerns the gene BRAF and colorectal cancer.